Sage Therapeutics, Biogen

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE. Per Sage Therapeutics,
SAGE Stock Up on Rejecting BIIB’s Proposal
Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Jan. 10.
Sage Therapeutics Initiates Strategic Review Process and Rejects Proposal from Biogen
Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process to explore various alternatives for the company.
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.
Sage rejects Biogen’s $469m takeover bid
Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.
Sage Therapeutics Rejects Biogen’s $469M Offer, Citing Undervaluation
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal significantly undervalues the company and does not align with shareholder interests.
No deal: Sage rejects Biogen's buyout offer, scouts for strategic alternatives
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. | The company's board of directors unanimously rejected partner Biogen's $469 million buyout proposal,
Sage rejects Biogen takeover and launches review
Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results in the mid-stage KINETIC 2 study, while Sage has reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease.
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of options, such as potential strategic transactions, business combinations, or the sale of the company.
Sage Therapeutics rejects Biogen bid, starts strategic review
Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%.
Hosted on MSN57m
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...
Sage Therapeutics initiates strategic review, rejects Biogen proposal
Sage Therapeutics (SAGE) announced that its board of directors has initiated a process to explore strategic alternatives for the company. The ...
STAT1d
Pharmalittle: We’re reading about RFK Jr. being open to seizing drug patents, pharma raising prices, and more
Robert Kennedy Jr. indicated he would consider authorizing the government to seize patents of high-priced medicines to lower ...
Hosted on MSN2d
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail
Biogen Inc. shares climbed 1.7% on Monday afternoon, reaching a nearly two-week high, as positive regulatory news countered ...